YOKNEAM, Israel, April 3, 2018 /PRNewswire/ --
Curewize Health Ltd. is a leader in the field of personalized
Curewize CTO, Dr. Nir Dotan: "Now that the clinical standardization of ProALLBM is completed, we will produce the lab test and offer for trial utility to the National Oncology groups. ProALL can reach many patients at an expedited pace through acceptance of the lab test by the national organizations."
Curewize CEO, Dr. Jennifer Yarden: "The successful clinical trial of our lead product paves the way for our product portfolio. Our plan is to create a large menu of lab tests by industrializing biological markers with good proof of concept using our platform technology."
About Curewize: Curewize product portfolio is based on its platform technology for quantifying microRNA, the master regulators of gene activity. Curewize pipeline includes a blood test, ProALLBL , for long-term and frequent monitoring of ALL patients, and a companion diagnostic lab test for deciding on the treatment of solid cancers with NAMPT and PARP inhibitors. Our biomarker directly controls NAMPT activity, a producer of cell energy, consumed by PARP for correcting DNA breaks in rapidly growing cancer cells. Curewize is a private company, owned by the co-founders Youdim Pharmaceutical Ltd., Dr. Jennifer Yarden and Mr. Ossie Weitzman. Curewize started its activity through the incubator program in June 2015 and due to its successful results is now continuing with an additional year under the Israeli Innovation Authority grant program.
Contact: Dr. Jennifer Yarden email@example.com +972-4-9090016
SOURCE Curewize Health Ltd
Subscribe to our Free Newsletters!
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...
Acanthosis nigricans is a skin condition in which discoloration and hyperpigmentation of the skin ...
Gastrointestinal Bleeding refers to hemorrhage that occurs from one or more portions of the ...View All